Evonik Industries is a leading German specialty chemical company with revenues of approximately $16 billion in 2025, focused on nutrition and care, smart materials, and specialty additives. Unlike BASF and Dow which are managing painful commodity portfolio exits, Evonik has already completed its transformation to a pure-play specialty chemical company — having divested its methacrylates business and its oil additives business. The company swung from a loss in 2023 to a profit in 2024, reflecting the improving earnings power of its specialty-focused portfolio. Evonik is investing in high-growth specialty segments including amino acids for animal nutrition, specialty surfactants for personal care, high-performance polymers for lightweight automotive applications, and membrane technologies for carbon capture and gas separation.

This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.


Topics Covered
• Strategic Directions — Specialty Focus, High-Growth Segment Investment, and Growth Priorities Through 2030
• Financial Performance — Revenue, EBITDA, Segment Results, R&D Investment, and Profitability Recovery 2023-2025
• SWOT Analysis — Competitive Advantages, Structural Vulnerabilities, Opportunities, and Risks
• Technological Know-How — Amino Acids, Specialty Surfactants, High-Performance Polymers, and Membrane Technologies
• Latest Products and Services — New Product Launches, Innovation Pipeline, and Technology Highlights
• M&A — Acquisitions, Divestitures, Joint Ventures, and Strategic Alliances 2023-2025
• Marketing Tactics — Specialty Positioning, Innovation-Led Marketing, and Customer Development
• Organization and Management — Leadership, Governance, and Workforce Developments